http://www.forbes.com/prnewswire/fee...rtner=moreover
Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
BNC105 is a new type of anti-cancer drug called a Vascular Disruption Agent (VDA) which blocks the blood supply to a solid tumour, effectively "starving" the tumour of nutrients. Pre-clinical data indicates that BNC105 has a dual mechanism of action with the ability to not only block the supply of nutrients to the tumour but also to directly destroy cancer cells. In addition, BNC105 is retained in the tumour at high levels for an extended period of time, enhancing its' anti-cancer effect.
Although VDAs have strong potential for use in combination with traditional cancer treatment options, including chemotherapy, preclinical data obtained with BNC105 to date suggest that its dual action is likely to enable its use as a single agent treatment. A large number of animals with BNC105 were cleared of their tumour burden after two cycles of treatment.
Threaded Mode